Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02115048 · ClinicalTrials.gov registry record · Phase 2
Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
A Phase 2 study, sponsored by Translational Research in Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT02115048 is a Phase 2 study that was terminated before completion, run by Translational Research in Oncology. The registered enrollment target is 44 participants.
The verdict
NCT02115048, a Phase 2 study, was terminated before completion, sponsored by Translational Research in Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the efficacy of treatment with afatinib plus letrozole to treatment with letrozole alone in women diagnosed with a specific type of breast cancer.
Interventions
- DRUG Letrozole
- DRUG Afatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2014-07 |
| Est. Completion | 2018-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02115048
The ClinicalTrials.gov registry entry for NCT02115048 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Translational Research in Oncology, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Letrozole is the first listed.
NCT02115048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02115048 about?
NCT02115048 is a clinical study titled "Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone". The purpose of the study is to compare the efficacy of treatment with afatinib plus letrozole to treatment with letrozole alone in women diagnosed with a specific type of breast cancer.
What is the current status of trial NCT02115048?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2014-07. Estimated completion is 2018-11.
What interventions are being tested in trial NCT02115048?
The interventions under investigation include: Letrozole (DRUG), Afatinib (DRUG).
Who is sponsoring clinical trial NCT02115048?
This trial is sponsored by Translational Research in Oncology, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.